Browsing by Author "Pan, Chong-Xian"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Analysis of the cytotoxic activity of carboplatin and gemcitabine combination
    (The International Institute of Anticancer Research, 2010-11) Wang, Sisi; Zhang, Hongyong; Evans, Christopher; Pan, Chong-Xian; Department of Pathology and Laboratory Medicine, IU School of Medicine
    Aim To determine if the drug doses and administration schedules of carboplatin and gemcitabine combination affect antitumor effects. Materials and Methods The inhibition of cell viability was measured by MTT assay. Median effect analysis was conducted to determine the cytotoxicity activity of carboplatin and gemcitabine combination. Cell cycle changes were analyzed by flow cytometry. Results Synergism was observed when the bladder cancer cell line 5637 cells were treated with gemcitabine followed by carboplatin or concurrent carboplatin/gemcitabine. In contrast, moderate antagonism was observed when cells were treated with carboplatin followed by gemcitabine. Cell cycle analysis showed that the combined effect of these two drugs was cell cycle disturbance. Conclusions Different doses and administration schedules affect the anti-tumor effect of carboplatin/gemcitabine combination that may have clinical significance in the treatment for bladder cancer.
  • Thumbnail Image
    Item
    Contemporary management of muscle-invasive bladder cancer
    (Taylor & Francis, 2012) Dall’Era, Marc A.; Cheng, Liang; Pan, Chong-Xian; Pathology and Laboratory Medicine, School of Medicine
    The current standard treatment for muscle-invasive nonmetastatic bladder cancer is neoadjuvant platinum-based chemotherapy followed by radical cystectomy. However, neoadjuvant chemotherapy is not widely accepted even with level 1 evidence. Adjuvant chemotherapy should be discussed if patients have not received neoadjuvant chemotherapy before surgery and have high-risk pathologic features. Although not considered standard of care, bladder-sparing therapy can be considered for highly selected patients and for those medically unfit for surgery. Even though there are no level 1 data, the treatment outcomes for highly select patients given bladder-sparing therapy appear promising, with many patients retaining a functional bladder. Personalized chemotherapy is currently being actively pursued to target the underlying molecular changes and tailor to individual needs.